Tempus AI's financials have significantly improved, with positive cash flow expected next quarter. Read why TEM stock is a ...

The new initiative aims to improve early detection by increasing access to screening in communities where accessing care is more difficult.

The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

WIPO reported that it received 273,900 applications under its Patent Cooperation Treaty (PCT) in 2024, representing a 0.5% increase compared to the previous year when the volume of applications fell ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here. Lower blood eosinophil counts ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...